BACKGROUND: Neurohormonal activation is a pathophysiological hallmark of acute and chronic heart failure (HF). The clinical significance of more recently discovered endogenous vasoactive hormones has not been well-characterized. METHODS AND RESULTS: In 154 subjects with stable, chronic systolic HF (New York Heart Association Class I-IV, left ventricular [LV] ejection fraction <or=40%), we measured plasma levels of urocortin 1 (UCN-1), urotensin II (UT-II), and endothelin-1 (ET-1) and performed comprehensive echocardiography with assessment of cardiac structure and performance. Adverse clinical events (all-cause mortality, cardiac transplantation or HF hospitalization) were prospectively tracked for a median of 39 months. Plasma levels of UCN-1 and ET-1 (but not UT-II) increased with LV diastolic dysfunction stage, right ventricular systolic dysfunction class, and mitral regurgitation severity (P < .01 for all). Higher plasma levels of UCN-1 and ET-1 (but not UT-II) predicted increased risk for adverse clinical events. After adjustment for age, LV ejection fraction, and plasma amino-terminal pro-B-type natriuretic peptide, plasma UCN-1 >or=12.1 pM (HR: 2.02, 95% CI: 1.08-3.93, P = .029) and ET-1 >or=2.29 pM (HR: 2.52, 95% CI: 1.24-5.03, P = .011) remained significant independent risk factors for adverse clinical events. CONCLUSION: Higher levels of plasma levels of UCN-1 and ET-1 but not UT-II were associated with worse LV diastolic performance and poorer long-term clinical outcomes in patients with chronic systolic HF. Copyright (c) 2010 Elsevier Inc. All rights reserved.
RCT Entities:
BACKGROUND: Neurohormonal activation is a pathophysiological hallmark of acute and chronic heart failure (HF). The clinical significance of more recently discovered endogenous vasoactive hormones has not been well-characterized. METHODS AND RESULTS: In 154 subjects with stable, chronic systolic HF (New York Heart Association Class I-IV, left ventricular [LV] ejection fraction <or=40%), we measured plasma levels of urocortin 1 (UCN-1), urotensin II (UT-II), and endothelin-1 (ET-1) and performed comprehensive echocardiography with assessment of cardiac structure and performance. Adverse clinical events (all-cause mortality, cardiac transplantation or HF hospitalization) were prospectively tracked for a median of 39 months. Plasma levels of UCN-1 and ET-1 (but not UT-II) increased with LV diastolic dysfunction stage, right ventricular systolic dysfunction class, and mitral regurgitation severity (P < .01 for all). Higher plasma levels of UCN-1 and ET-1 (but not UT-II) predicted increased risk for adverse clinical events. After adjustment for age, LV ejection fraction, and plasma amino-terminal pro-B-type natriuretic peptide, plasma UCN-1 >or=12.1 pM (HR: 2.02, 95% CI: 1.08-3.93, P = .029) and ET-1 >or=2.29 pM (HR: 2.52, 95% CI: 1.24-5.03, P = .011) remained significant independent risk factors for adverse clinical events. CONCLUSION: Higher levels of plasma levels of UCN-1 and ET-1 but not UT-II were associated with worse LV diastolic performance and poorer long-term clinical outcomes in patients with chronic systolic HF. Copyright (c) 2010 Elsevier Inc. All rights reserved.
Authors: Lakshmi Pulakat; Vincent G DeMarco; Sivakumar Ardhanari; Anand Chockalingam; Rukhsana Gul; Adam Whaley-Connell; James R Sowers Journal: Am J Physiol Regul Integr Comp Physiol Date: 2011-08-03 Impact factor: 3.619
Authors: Sanjay Singh; Scott Sayers; James S Walter; Donald Thomas; Robert S Dieter; Lisa M Nee; Robert D Wurster Journal: J Am Heart Assoc Date: 2013-08-19 Impact factor: 5.501
Authors: Isabel Mayoral-González; Eva M Calderón-Sánchez; Isabel Galeano-Otero; Marta Martín-Bórnez; Encarnación Gutiérrez-Carretero; María Fernández-Velasco; Nieves Domenech; María Generosa Crespo-Leiro; Ana María Gómez; Antonio Ordóñez-Fernández; Abdelkrim Hmadcha; Tarik Smani Journal: Mol Ther Nucleic Acids Date: 2022-01-10 Impact factor: 8.886